CEO: Shoshana Shendelman

Exit: Applied Therapeutics had an IPO in May, 2019. It was one of the top 4 most successful IPOs of 2019. (NASDAQ:APLT)

Visit Website

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a potential treatment for Galactosemia, a devastating, inherited, rare disorder that affects how the body metabolizes a type of sugar called galactose. Galactosemia has no known cure or approved treatment.  This disorder can greatly affect children’s development, causing severe and permanent motor, speech and cognitive deficiencies; cataracts; tremor; and ovarian insufficiency.

Applied Therapeutics also is developing a potential treatment for Diabetic Cardiomyopathy, a rapidly progressing degenerative disorder that affects 17%-24% of people with diabetes and causes the heart to become fibrotic, leading to heart failure. There is no current treatment for this condition.  Applied therapeutics’ drug candidate presents an opportunity to potentially halt disease progression and prevent worsening of the heart damage.